Cefpodoxime Proxetil Prices Gain Support in July 2026 Amid Demand and Freight Costs Support

The prices of Cefpodoxime Proxetil remained firm during the first half of July 2026 as CFR Houston Cefpodoxime Proxetil offers strengthened with U.S. generic manufacturers resuming active procurement following seasonal demand. FDA-approved supplier constraints continued to maintain a structural premium, while qualified Chinese Cefpodoxime Proxetil manufacturers reported tight spot availability. Rising Asia–U.S. freight rates, coupled with geopolitical tensions, added further cost pressure on landed imports, supporting firmer Cefpodoxime Proxetil prices despite adequate overall supply availability.During June 2026, Cefpodoxime Proxetil (USP) CFR Houston prices declined by 1.50% due to subdued spot demand despite increasing logistics costs. Early-month buying remained weak as group purchasing organizations delayed procurement while ample exports from India and China kept supply comfortable. Hospital demand remained the primary consumption driver, whereas retail pharmacies continued inventory drawdowns. The pharmaceutical formulation sector recorded stable demand, supported by pediatric antibiotic production. Maintenance at upstream 7-ACA facilities and regulatory inspections tightened feedstock availability, while higher freight costs and port congestion increased landed costs without significantly restricting supply. Looking ahead, Cefpodoxime Proxetil prices are anticipated to strengthen through the coming months as procurement activity improves, freight costs remain elevated, and supplier constraints continue supporting the market.